



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 14 Aug 2023 (#30)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

## Important Notices

**Fogarty-leDEA Mentorship Program (FIMP):** Current and former Fogarty D43 trainees and leDEA-affiliated regional investigators develop skills in study design, data management, analysis, interpretation, and dissemination of research involving large HIV clinical databases generated within leDEA. **Application deadline:** October 23, 2023.

Informational webinars:

- Tuesday, August 1 at 9 pm ET/USA
- Thursday, August 3 at 9 am ET/USA
- Friday, August 4 at 9 am ET/USA

**Application portal:** Apply online, get webinar information and answers to frequently asked questions

**NOT-OD-23-161 NIH Application Instruction Updates – Data Management and Sharing (DMS) Costs.** Effective for applications submitted for due dates on or after October 5, 2023, NIH will no longer require the use of the single DMS cost line item. NIH recognizes that DMS costs may be requested in many cost categories. Therefore, in line with our standard budget instructions, DMS costs must be requested in the appropriate cost category, e.g., personnel, equipment, supplies, and other expenses. While the single cost line item is no longer required, NIH will require applicants to specify estimated DMS cost details within the “Budget Justification” attachment.

## Parent Announcements

**NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates *Expiration Date: May 8, 2023* **Modified Key Dates** *Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest

[NOT-HL-23-102](#) Promoting implementation research to address HIV-associated comorbidities and risk factors within well-established cohorts (R01 Clinical Trial Optional). This NOSI seeks to support dissemination and implementation (D&I) research proposals leveraging well-established cohorts of people living with HIV (PLWH) to increase the acceptability, feasibility, implementation, scale-up, scale-out, and sustainability of evidence-based interventions (EBIs) that target comorbid conditions and diseases. ***This NOSI hopes to promote new or existing collaborative efforts between observational, interventional, and D&I scientists, which is a crucial next step to ensure maximal public health impact of clinical trial and cohort studies.*** Investigators are encouraged to utilize lessons learned from ongoing or legacy cohort studies alongside other data sources to strengthen D&I research projects targeting PLWH. Further, there are opportunities to evaluate both the effectiveness and D&I outcomes of the selected EBIs, based on the level evidence to support their implementation. This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 7, 2026.

## Notice of Funding Opportunity (NOFO)

### 1. Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-245](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to October 05, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health.

**Budget:** Application budgets are expected to be no more than \$250,000 per year in direct costs and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. Applications may request a project period up to 4 years.

### 2. Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-249](#)

**Type:** R34

**Application Due Date:** October 16, 2023 through to July 16, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

**Budget:** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this NOFO may not exceed 3 years.

### 3. Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-250](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to July 05, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

**Budget:** Direct costs may not exceed \$500,000 without prior approval. The maximum project period is five years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

#### 4. Alcohol Health Services Research (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-251](#)

**Type:** R01

**Application Due Date:** October 05, 2023 and July 05, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

**Budget:** Direct costs may not exceed \$500,000 without prior approval (see Section IV. Application and Submission Information). The maximum project period is five years.

#### 5. Alcohol Health Services Research (R34 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-252](#)

**Type:** R34

**Application Due Date:** October 16, 2023 through to July 16, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

**Budget:** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this NOFO may not exceed 3 years.

#### 6. Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-259](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, or treatment of cancer. A distinguishing feature of each application to this NOFO will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the NOFO acts more as a funding mechanism for driving translational research in imaging than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or establish new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This NOFO defines innovation as the likelihood to deliver a new capability to end users. This funding announcement will support clinical trials that test functionality or validate performance in the chosen setting. However, this NOFO is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

**Budget:** Application budget is limited to less than \$500,000 direct cost per year and must reflect the actual needs of the proposed project. The maximum project period is 5 years.

#### 7. Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-264](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to July 05, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 3 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application.

#### 8. Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-273](#)

**Type:** R01

**Application Due Date:** October 05, 2023 through to March 05, 2026 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

#### 9. Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-24-028](#)

**Type:** R01

**Application Due Date:** November 03, 2023 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) invites innovative R01 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older-aged racial and/or ethnic subgroups considered to be a minority in the US (see [OMB Directive 15](#)) to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). High-risk/high-payoff projects that lack preliminary data are more appropriate for the companion NOFO, [RFA-AG-24-029](#), which invites Exploratory/Developmental Research Grant (R21) applications.

**Budget:** NIA intends to commit \$3,000,000 in FY 2024 to fund 6 awards. Applications budgets are limited to \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

#### 10. Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD (R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-24-029](#)

**Type:** R21

**Application Due Date:** November 03, 2023 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) invites innovative R21 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older aged racial and/or ethnic subgroups considered to be a minority in the US (see [OMB Directive 15](#)) to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Applications with preliminary data are encouraged to apply to companion NOFO [RFA-AG-24-028](#), which invites Research Project Grant (R01) applications. However, high-risk/high-payoff projects that lack preliminary data may be more appropriate for this NOFO.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

#### 11. Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-24-045](#)

**Type:** R01

**Application Due Date:** October 05, 2023 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The National Institute on Aging (NIA) invites R01 applications that propose human studies to better understand factors underlying response variability to exercise training in older adults through this Notice of Funding Opportunity (NOFO). This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. Additionally, this NOFO encourages transdisciplinary studies utilizing innovative design methods and analytical approaches combined with clinical phenotyping to disentangle the complicated relationships between endogenous and exogenous factors that drive response variation to exercise. Elucidating factors and mechanisms that underlie variations in exercise response, and the extent to which these factors are modifiable, may enable more precise and efficacious exercise prescriptions to optimize the clinical efficacy of exercise training in older adults.

**Budget:** NIA intends to commit \$3,000,000 in FY 2024 to fund up to 3 awards. Application budgets should reflect the actual needs of the proposed project and cannot exceed \$1,000,000 in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

#### 12. HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-24-021](#)

**Type:** R01

**Application Due Date:** November 07, 2023 through to February 06, 2025 due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring

with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.

**Budget:** The NIH HEAL (Helping to End Addiction Long-term) Initiative intends to commit an estimated total of \$4 million to fund 3-4 awards in FY 2024. Awards pursuant to this funding opportunity are contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets should not exceed \$650,000 direct costs per year, and should be consistent with the complexity and needs of the proposed project. Annual inflationary increases are not allowed. Applications may request up to five years of support.

Research Development and Support Division (RDSD) & Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105